Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC48-ADC in HER2-negative Urothelial Cancer
NCT04073602Phase 2Completed
- Sponsor
- RemeGen
- Start
- Aug 2019
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of disitamab vedotin in urothelial carcinoma (UC), sponsored by RemeGen. Started Aug 2019; status: completed.
02
Drugs
disitamab vedotin
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04073602.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073602.